BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20170101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181204
DTEND;VALUE=DATE:20181207
DTSTAMP:20260515T005823
CREATED:20180808T120122Z
LAST-MODIFIED:20180808T120525Z
UID:17076-1543881600-1544140799@www.pharmajournalist.com
SUMMARY:4th Annual Oncolytic Virotherapy Summit
DESCRIPTION:The 4th Oncolytic Virotherapy Summit is dedicated to improving the commercial success of oncolytic viruses\, in stand-alone and combination therapies. \n\nAs many oncolytic viruses progress through the clinical pipelines\, drug developers need to ensure that their therapies are safe\, efficacious and commercially viable. Make sure you stay ahead of the game and join Oncolytic Virotherapy Summit\, where you will have an opportunity to pick the brains of 100+ senior industry peers and tackle your challenges in discovery\, clinical development\, manufacturing and regulations of oncolytic virotherapy. \nThis year we will be incorporating commercial insights from companies such as Merck\, Virogen\, Sagetis\, Lokon Pharma\, Replimmune\, Western Oncolytics\, DNAtrix and many more\, which will allow you to learn from their case studies and improve your development strategies. Participate in the interactive roundtable and workshops to build strategies that maximise success in the clinic and commercially. \nSounds interesting? Find out more – get free event brochure here: http://bit.ly/2KzCLIh
URL:https://www.pharmajournalist.com/event/4th-annual-oncolytic-virotherapy-summit/
LOCATION:Hilton Boston Back Bay Hotel\, 40 Dalton St\, Boston\, MA\, 02115\, United States
ORGANIZER;CN="Hanson Wade":MAILTO:maggie.pang@oncolyticvirotherapies.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181204
DTEND;VALUE=DATE:20181206
DTSTAMP:20260515T005823
CREATED:20180821T073305Z
LAST-MODIFIED:20180821T073427Z
UID:17294-1543881600-1544054399@www.pharmajournalist.com
SUMMARY:Skin Microbiome Asia
DESCRIPTION:Skin Microbiome Asia | 4-5 December 2018 | Hong Kong – As K-Beauty and J-Beauty continue to storm the world\, beauty start-ups are also emerging from Australia\, India and across Southeast Asia.  China\, Singapore and Hong Kong remain mecca markets for international companies launching products into the region. There has never been a better time for cosmetics professionals to meet in Asia. \n \n150+ industry experts will be gathering in Hong Kong this December to learn about the science behind the products from companies like Unilever\, Cosmax\, Mother Dirt and more. \nJoin multinationals\, independent beauty brands\, sequencing companies\, regulators\, pharma & biotech companies and academia to build your network throughout Asia Pacific. \nInterested to learn more? Take a look at our agenda here: http://bit.ly/SkinAsiaAgenda \nOr take advantage of our Super Early Bird Pricing and book your pass here: http://bit.ly/SkinAsiaRegistration \nPraise for the event: \n“An incredible event… Fast paced and full of new and relevant information from a variety of perspectives\, each of which provide a complete and extensive snapshot of the industry and the future of microbiome friendly products”  – TrūAura Beauty \n“The value of this conference was absolutely unparalleled! I not only saw many old friends\, collaborators and partners\, but also met many new ones as well.”  – ProdermIQ \nTo learn more about Skin Microbiome Asia\, and to register online\, visit www.skinmicrobiomecongressasia.com
URL:https://www.pharmajournalist.com/event/skin-microbiome-asia/
LOCATION:Hong Kong\, Venue TBC
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181204
DTEND;VALUE=DATE:20181207
DTSTAMP:20260515T005823
CREATED:20180926T144030Z
LAST-MODIFIED:20180926T144030Z
UID:17791-1543881600-1544140799@www.pharmajournalist.com
SUMMARY:CBI’s Clinical Trial Agreement Series
DESCRIPTION:Designed to maximize your time out of the office\, CBI’s three-day Clinical Trial Agreement conference series allows your team to select the content that best meets your business objectives. Attend your preferred event or BOTH for maximum value\, learning and benchmarking. The Clinical Trial Legal and Contracting Forum\, taking place December 4-5 in Philadelphia\, serves as the only meeting that is singularly focused on the detailed legal and contracting issues that relate to clinical agreements of all types. The Clinical Trial Financial Management summit\, taking place December 5-6 in Philadelphia\, is designed to arm sponsors\, CROs\, AMCs and sites with the insights they need to develop\, negotiated and manage the financial aspects of clinical trial agreements. \nTo learn more about this event\, visit www.cbinet.com/ctafinance
URL:https://www.pharmajournalist.com/event/cbis-clinical-trial-agreement-series/
LOCATION:Wyndham Philadelphia Historic District\, 400 Arch Street\, Philadelphia\, PA\, 19106\, United States
ORGANIZER;CN="CBI%2C a division of UBM Americas":MAILTO:cbireg@cbinet.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20181204
DTEND;VALUE=DATE:20181206
DTSTAMP:20260515T005823
CREATED:20181010T095555Z
LAST-MODIFIED:20181010T095555Z
UID:17959-1543881600-1544054399@www.pharmajournalist.com
SUMMARY:BioFIT
DESCRIPTION:EARLY-STAGE INNOVATIONS | ACADEMIA-INDUSTRY COLLABORATIONS | TECHNOLOGY TRANSFER | SEED INVESTMENT  \nWith the highest attending rate of TTOs\, research institutes and academia together with big pharma\, emerging and small biotech\, diagnostics companies\, pre-seed / seed / Series A investors\, BioFIT is the leading partnering event in Europe for technology transfer\, academia-industry collaborations and early-stage innovations in the field of Life Sciences. BioFIT is also the European marketplace for pre-seed\, seed and Series A investment in Life Sciences. \nWHY ATTEND BIOFIT? \nOut of 1\,000 BioFIT attendees\, 1\,000 deals have been generated. The breakdown in terms of nature of deals is the following: \n\n35% of collaborative research projects\n30% of licensing deals\n15% of equity investment deals\n20% of services deals\n\nEstimate based on the measurement of 2015 and 2016 delegates’ outcomes \nKEY FIGURES: \n\n1\,200+ delegates\n800+ organisations\n35+ countries represented\n1\,000 deals generated in 2017\n\nINSIDE THE EVENT: \n\nA business convention with pre-qualified one-to-one meetings (partneringONE platform from EBD Group)\nIdentification of would-be CEOs\nConferences and roundtable discussions\nOral presentations of start-ups and licensing opportunities stemming from academia\nAn exhibition area\nInformal networking evenings\n\nWebsite: www.biofit-event.com\nTwitter: @BIOFIT_EVENT \nContact:\nMargaux Satola\nBusiness Development Manager\nmsatola@eurasante.com\n+33 (0)3 59 39 01 82
URL:https://www.pharmajournalist.com/event/biofit/
LOCATION:Lille Grand Palais  1 boulevard des Cités Unies  59000 Lille\, FRANCE\, France
ORGANIZER;CN="Eurasant%C3%A9%2C NHL Cluster%2C Alsace BioValley":MAILTO:biofit@eurasante.com
END:VEVENT
END:VCALENDAR